QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Urothelial Carcinoma
Head and Neck Squamous Cell Carcinoma
Merkel Cell Carcinoma
Melanoma
Renal Cell Carcinoma
Gastric Cancer
Cervical Cancer
Hepatocellular Carcinoma
Microsatellite Instability
Mismatch Repair Deficiency
Colorectal Cancer

Interventions

DRUG: N-803 + Pembrolizumab
DRUG: N-803 + Nivolumab
DRUG: N-803 + Atezolizumab
DRUG: N-803 + Avelumab
DRUG: N-803 + Durvalumab
DRUG: N-803 + Pembrolizumab + PD-L1 t-haNK
DRUG: N-803 + Nivolumab + PD-L1 t-haNK
DRUG: N-803 + Atezolizumab + PD-L1 t-haNK
DRUG: N-803 + Avelumab + PD-L1 t-haNK
DRUG: N-803 + Durvalumab + PD-L1 t-haNK
DRUG: N-803 + Docetaxel + Pembrolizumab
DRUG: N-803 + Docetaxel + Nivolumab

Sponsor

ImmunityBio, Inc.